Acacia Drug Patent Portfolio

Acacia owns 2 orange book drugs protected by 16 US patents Given below is the list of Acacia's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11357753 Rescue treatment of post operative nausea and vomiting 09 Feb, 2038
Active
US9084765 Use of amisulpride as an anti-emetic 26 Feb, 2034
Active
US9827251 Dosing regimen for sedation with CNS 7056 (remimazolam) 13 Jan, 2034
Active
US9561236 Dosing regimen for sedation with CNS 7056 (Remimazolam) 30 Apr, 2033
Active
US10052334 Dosing regimen for sedation with CNS 7056 (remimazolam) 07 Nov, 2031
Active
US10195210 Dosing regimen for sedation with CNS 7056 (Remimazolam) 07 Nov, 2031
Active
US10342800 Dosing regimen for sedation with CNS 7056 (Remimazolam) 07 Nov, 2031
Active
US10722522 Dosing regimen for sedation with CNS 7056 (remimazolam) 07 Nov, 2031
Active
US9737547 Dosing regimen for sedation with CNS 7056 (Remimazolam) 07 Nov, 2031
Active
US10525033 Use of amisulpride as an anti-emetic 10 Mar, 2031
Active
US9545426 Use of amisulpride as an anti-emetic 10 Mar, 2031
Active
US9889118 Use of amisulpride as an anti-emetic 10 Mar, 2031
Active
US10472365 Short-acting benzodiazepine salts and their polymorphic forms 10 Jul, 2027
Active
US10961250 Short-acting benzodiazepine salts and their polymorphic forms 10 Jul, 2027
Active
US9777007 Short-acting benzodiazepine salts and their polymorphic forms 10 Jul, 2027
Active
US9914738 Short-acting benzodiazepine salts and their polymorphic forms 10 Jul, 2027
Active


Given below is the list of recent legal activities going on the following drug patents of Acacia.

Activity Date Patent Number
Patent litigations
Patent Term Extension Certificate 21 May, 2024 US9827251
Payment of Maintenance Fee, 4th Year, Large Entity 29 Jan, 2024 US10722522
Notice of Final Determination -Eligible 20 Dec, 2023 US9827251
Email Notification 19 Dec, 2023 US9777007
Change in Power of Attorney (May Include Associate POA) 19 Dec, 2023 US9777007
Change in Power of Attorney (May Include Associate POA) 18 Dec, 2023 US9827251
Change in Power of Attorney (May Include Associate POA) 18 Dec, 2023 US9914738
Change in Power of Attorney (May Include Associate POA) 18 Dec, 2023 US10472365
Email Notification 18 Dec, 2023 US9827251
Email Notification 18 Dec, 2023 US10961250
Change in Power of Attorney (May Include Associate POA) 18 Dec, 2023 US9561236
Change in Power of Attorney (May Include Associate POA) 18 Dec, 2023 US10961250
Email Notification 18 Dec, 2023 US10472365
Email Notification 18 Dec, 2023 US9561236
Email Notification 18 Dec, 2023 US9914738


Acacia's Family Patents

Acacia drugs have patent protection in a total of 29 countries. It's US patent count contributes only to 21.3% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Acacia Drug List

Given below is the complete list of Acacia's drugs and the patents protecting them.


1. Barhemsys

Barhemsys is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11357753 Rescue treatment of post operative nausea and vomiting 09 Feb, 2038
(13 years from now)
Active
US9084765 Use of amisulpride as an anti-emetic 26 Feb, 2034
(9 years from now)
Active
US10525033 Use of amisulpride as an anti-emetic 10 Mar, 2031
(6 years from now)
Active
US9545426 Use of amisulpride as an anti-emetic 10 Mar, 2031
(6 years from now)
Active
US9889118 Use of amisulpride as an anti-emetic 10 Mar, 2031
(6 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Barhemsys's drug page


2. Byfavo

Byfavo is protected by 11 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9827251 Dosing regimen for sedation with CNS 7056 (remimazolam) 13 Jan, 2034
(9 years from now)
Active
US9561236 Dosing regimen for sedation with CNS 7056 (Remimazolam) 30 Apr, 2033
(8 years from now)
Active
US10052334 Dosing regimen for sedation with CNS 7056 (remimazolam) 07 Nov, 2031
(7 years from now)
Active
US10195210 Dosing regimen for sedation with CNS 7056 (Remimazolam) 07 Nov, 2031
(7 years from now)
Active
US10342800 Dosing regimen for sedation with CNS 7056 (Remimazolam) 07 Nov, 2031
(7 years from now)
Active
US10722522 Dosing regimen for sedation with CNS 7056 (remimazolam) 07 Nov, 2031
(7 years from now)
Active
US9737547 Dosing regimen for sedation with CNS 7056 (Remimazolam) 07 Nov, 2031
(7 years from now)
Active
US10472365 Short-acting benzodiazepine salts and their polymorphic forms 10 Jul, 2027
(2 years from now)
Active
US10961250 Short-acting benzodiazepine salts and their polymorphic forms 10 Jul, 2027
(2 years from now)
Active
US9777007 Short-acting benzodiazepine salts and their polymorphic forms 10 Jul, 2027
(2 years from now)
Active
US9914738 Short-acting benzodiazepine salts and their polymorphic forms 10 Jul, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Byfavo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List